ReviewJournal of aerosol medicine and pulmonary drug delivery2016
Bridging the Gap Between Science and Clinical Efficacy: Physiology, Imaging, and Modeling of Aerosols in the Lung.
Review in Journal of aerosol medicine and pulmonary drug delivery, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 84 citations in OpenAlex.
- Sufentanil EC50 for endotracheal intubation with aerosol inhalation of carbonated lidocaine by ultrasonic atomizer.BMC anesthesiology · 2021Trial
- Design and development of a high-throughput multipattern aerosol deposition device for respiratory toxicity and health-risk assessment (MARTHA).Journal of aerosol science · 2026Article
- Role of antimicrobial peptide-based biomaterials in respiratory tract infections control.BMC microbiology · 2026Review
- In Vitro Evaluation of the Effect of Size and PEGylation on Inhalable Liposomes for Pulmonary Drug Delivery.Nanomaterials (Basel, Switzerland) · 2026Article
- Applications of AI/ML in accelerating the development of pulmonary drug delivery system.Acta pharmaceutica Sinica. B · 2026Review
- Impact of normal, obstructive, and restrictive breathing patterns on aerosol drug delivery with jet and mesh nebulizers in simulated spontaneously breathing adults.Canadian journal of respiratory therapy : CJRT = Revue canadienne de la therapie respiratoire : RCTR · 2025Article
- Article
- Aerosolised micro and nanoparticle: formulation and delivery method for lung imaging.Clinical and translational imaging · 2023Review
- Basement membrane properties and their recapitulation in organ-on-chip applications.Materials today. Bio · 2022Review
- Targeted delivery of inhalable drug particles in a patient-specific tracheobronchial tree with moderate COVID-19: A numerical study.Powder technology · 2022Article
- Nanomedicine formulations for respiratory infections by inhalation delivery: Covid-19 and beyond.Medical hypotheses · 2022Article
- A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease.Respiratory research · 2021Article
- Dry Powder Inhalers in the Digitalization Era: Current Status and Future Perspectives.Pharmaceutics · 2021Review
- Innovating on Inhaled Bioequivalence: A Critical Analysis of the Current Limitations, Potential Solutions and Stakeholders of the Process.Pharmaceutics · 2021Review
- Article
- Comparative in-vitro Study of the Trachospray, a New Device for Topical Anaesthesia of the Upper Airway.Medical devices (Auckland, N.Z.) · 2021Article
- Preclinical Development of Orally Inhaled Drugs (OIDs)-Are Animal Models Predictive or Shall We Move Towards In Vitro Non-Animal Models?Animals : an open access journal from MDPI · 2020Article
- Ventilation/Perfusion Relationships and Gas Exchange: Measurement Approaches.Comprehensive Physiology · 2020Review
- Feasibility of Aerosolized Alpha-1 Antitrypsin as a Therapeutic Option.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2020Review
- Engineering Preclinical Tools and Therapeutics to Understand and Treat COVID-19.Delaware journal of public health · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 6 institutions in 3 countries.
Funding
Abstract
Development of a new drug for the treatment of lung disease is a complex and time consuming process involving numerous disciplines of basic and applied sciences. During the 2015 Congress of the International Society for Aerosols in Medicine, a group of experts including aerosol scientists, physiologists, modelers, imagers, and clinicians participated in a workshop aiming at bridging the gap between basic research and clinical efficacy of inhaled drugs. This publication summarizes the current consensus on the topic. It begins with a short description of basic concepts of aerosol transport and a discussion on targeting strategies of inhaled aerosols to the lungs. It is followed by a description of both computational and biological lung models, and the use of imaging techniques to determine aerosol deposition distribution (ADD) in the lung. Finally, the importance of ADD to clinical efficacy is discussed. Several gaps were identified between basic science and clinical efficacy. One gap between scientific research aimed at predicting, controlling, and measuring ADD and the clinical use of inhaled aerosols is the considerable challenge of obtaining, in a single study, accurate information describing the optimal lung regions to be targeted, the effectiveness of targeting determined from ADD, and some measure of the drug's effectiveness. Other identified gaps were the language and methodology barriers that exist among disciplines, along with the significant regulatory hurdles that need to be overcome for novel drugs and/or therapies to reach the marketplace and benefit the patient. Despite these gaps, much progress has been made in recent years to improve clinical efficacy of inhaled drugs. Also, the recent efforts by many funding agencies and industry to support multidisciplinary networks including basic science researchers, R&D scientists, and clinicians will go a long way to further reduce the gap between science and clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.